{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:47:02Z","timestamp":1769431622041,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1099,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hexal AG\/Sandoz International GmbH"},{"name":"Hexal AG\/Sandoz International GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1093\/annonc\/mdw309","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T07:39:08Z","timestamp":1477640348000},"page":"2039-2045","source":"Crossref","is-referenced-by-count":34,"title":["Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Aapro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Denhaerynck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Krendyukov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gorray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw309_bb0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2009.01.003","article-title":"Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics","volume":"72","author":"Wingard","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdw309_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw309_bb0020","series-title":"2015 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Myeloid growth factors","author":"National Comprehensive Center Network","year":"2015"},{"key":"10.1093\/annonc\/mdw309_bb0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdw309_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2007.01.008","article-title":"Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel","volume":"63","author":"Gridelli","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdw309_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.critrevonc.2010.03.008","article-title":"Febrile neutropenia: a critical review of the initial management","volume":"78","author":"Klastersky","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdw309_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.critrevonc.2010.02.005","article-title":"Prevention of febrile neutropenia in chemotherapy-treated cancer patients: pegylated versus standard myeloid colony stimulating factors. Do we have a choice?","volume":"78","author":"Klastersky","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdw309_bb0045","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw309_bb0050","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw309_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia","volume":"100","author":"Crawford","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw309_bb0060","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1517\/14712598.4.12.1897","article-title":"The colony-stimulating factors: use to prevent and treat neutropenia and its complications","volume":"4","author":"Komorokji","year":"2004","journal-title":"Exp Opin Biol Ther"},{"key":"10.1093\/annonc\/mdw309_bb0065","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw309_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.critrevonc.2010.01.014","article-title":"Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim","volume":"77","author":"Gasc\u00f3n","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdw309_bb0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.critrevonc.2011.01.006","article-title":"Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: protocol amendments","volume":"77","author":"Gasc\u00f3n","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdw309_bb0080","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","article-title":"Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)","volume":"24","author":"Gasc\u00f3n","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdw309_bb0085","series-title":"Regression Modeling Strategies","author":"Harrell","year":"2001"},{"key":"10.1093\/annonc\/mdw309_bb0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for some traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"10.1093\/annonc\/mdw309_bb0095","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2288-12-82","article-title":"Interpreting the concordance statistic of a logistic regression model: relation to the variance and odds ratio of a continuous explanatory variable","volume":"12","author":"Austin","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1093\/annonc\/mdw309_bb0100","unstructured":"DL Cassell. BootstrapMania!: Re-Sampling the SAS\u00ae Way. SAS Institute Inc. 2010. In Proceedings of the 2010 SAS Global Forum, Paper 268\u20132010. Cary, NC: SAS Institute Inc."},{"key":"10.1093\/annonc\/mdw309_bb0105","first-page":"CD004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdw309_bb0110","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw309_bb0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"Thirty years follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdw309_bb0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mdw309_bb0125","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/s11523-011-0193-6","article-title":"What do prescribers think of biosimilars?","volume":"7","author":"Aapro","year":"2012","journal-title":"Targ Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/11\/2039\/19446527\/mdw309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:51:38Z","timestamp":1624693898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419358296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0923753419358296"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw309","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}